The purpose of this study is to Evaluate the efficacy and safety of Hepabulin IV (HBIG, a study drug) after liver transplantation.
A 52-week, Multi-center, Open label, Single arm, Phase 3 Study to Evaluate the Efficacy and Safety of Hepabulin IV in HBsAg positive Liver Transplantation recipients
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
PREVENTION
Masking
NONE
Enrollment
87
I.V.
SKChemicals
Seongnam, Gyunggi-do, South Korea
HBV(HBsAg) recurrence
Time frame: 52 weeks
Time to recurrence
Time frame: 52 weeks
Survival
Time frame: 52 weeks
viral Marker of HBV
Time frame: 52 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.